Abstract
Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. 177Lu-PSMA radioligand therapy is mainly used for patients with endstage prostate cancer. This report describes two patients: one patient with a multiple recurrences and one with extensive metastastic disease during the first visit. Both these patients were treated with 177Lu-PSMA radioligand therapy with major response, i.e. complete response by imaging and substantial reduction of PSA. 177Lu-PSMA radioligand therapy gave only mild adverse effects. In conclusion, patients with metastatic prostate cancer, 177Lu-PSMA-617 radioligand therapy had an attractive therapeutic profile which had to be adjusted according to the patient´s need.
Highlights
Most of the patients who have local prostate cancer will be cured totally without any serious side effects especially if high dose rate brachytherapy can be used [1]
In recent years hormone therapy is enhanced more and more often by Docetaxel chemotherapy already before castration resistance emerges according to the results of CHARTEED and STAMPEDE trials [2, 3]
If tumor cells appears to be positive for PSMA in PET-CT scanning, that positivity can be used for treatment, where intravenously administered PSMA-labelled Lu-177 (177Lutetium-PSMA) radiopharmaceutical targets and destroys PSMA-positive metastases
Summary
Lu-177-PSMA treatment for metastatic prostate cancer – case examples of miracle responses. This report describes two patients: one patient with a multiple recurrences and one with extensive metastastic disease during the first visit Both these patients were treated with 177Lu-PSMA radioligand therapy with major response, i.e. complete response by imaging and substantial reduction of PSA. Patients with metastatic prostate cancer, 177Lu-PSMA-617 radioligand therapy had an attractive therapeutic profile which had to be adjusted according to the patients need. Терапия радиолигандом 177Lu-ПСМА в основном используется у пациентов с распространённой формой рака простаты. Пациенты с метастатическим раком простаты, подвергнутые терапии радиолигандом 177Lu-ПСМА-617 имели благоприятный терапевтический профиль, который был скорректирован в соответствии с потребностями пациента. Joensuu LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
